Caricamento...
Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer
BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi comb...
Salvato in:
| Pubblicato in: | BMC Med Genomics |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5069826/ https://ncbi.nlm.nih.gov/pubmed/27756306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-016-0225-2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|